Showing posts with label NMDA receptor. Show all posts
Showing posts with label NMDA receptor. Show all posts

Monday, April 16, 2012

Dementia therapy-patch or pill (part 2)

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Family Practice News

The NMDA (N-methyl-d-aspartate) receptor antagonist memantine is also approved for patients with mild to moderate Alzheimer’s, with optimal dosing titration to 10 mg b.i.d. "Side effects are quite rare, but can include somnolence, headache, and dizziness," said Dr. Cummings, who is also chair of neurotherapeutics at the Cleveland Clinic’s Neurological Institute. "Most patients, by the time they reach mid-disease, are on both a cholinesterase inhibitor and memantine."

Other treatment options include the medical foods CerefolinNAC and Axona, which are generally recognized as safe by the Food and Drug Administration and are available by prescription. "No demonstration of clinical benefit is required for these agents," Dr. Cummings said. "The data set supporting medical foods is not as robust as the data set supporting cholinesterase inhibitors."

CerefolinNAC is a combination of vitamin B6, vitamin B12, and folate that Dr. Cummings uses for hyperhomocysteinemia. "I know that high levels of homocysteine are correlated with cognitive impairment, so I try to reduce that by giving CerefolinNAC," he said. "However, there are no data which prove that lowering will necessarily improve the prognosis of the patient. What you are doing is piecing together various types of data to support that use, but it’s not as strong as a double-blind, placebo-controlled trial showing a direct benefit."

Axona is a proprietary formulation of medium-chain triglycerides that increase plasma concentrations of ketone bodies. "This is considered an energy source for neurons," Dr. Cummings said.

Dr. Cummings disclosed that he has provided consultation to the following pharmaceutical companies: Abbott, Acadia, Adamas, Anavex, Astellas, Avanir, Bayer, BMS, Eisai, EnVivo, ExonHit, Janssen, Forest, Genentech, GSK, Lundbeck, Merck, Neurokos, Novartis, Otsuka, Pfizer, Prana, QR Pharma, Sanofi-Aventis, and Takeda.

Thursday, February 2, 2012

Study adds piece to the Alzheimer's puzzle

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Toronto Sun

CALGARY - Research out of the University of Calgary has endeavoured to further explain why brain cells in Alzheimer's disease patients die.

The study by scientists at the U of C's Hotchkiss Brain Institute shows the cells are being killed off as the result of a malfunctioning neurotransmitter receptor called NMDA, which is responsible for memory and learning.

It had previously been shown a malformed protein exists in Alzheimer's disease patients' brains. The recent study used animal models to show a new mechanism of how the protein kills cells.

Dr. Gerald Zamponi and Dr. Peter Stys found the NMDA receptor is strongly regulated by copper, and if copper is prevented from regulating it — as it is in Alzheimer's disease— the cells are over-stimulated and eventually die.

The malformed protein is believed to steal copper from the NMDA receptor, causing the cell deaths.

Zamponi said the discovery may open doors for the development of treatments for the neurodegenerative disease.

"We think we can design drugs that restore the normal function of the receptor, therefore protecting brain cells," he said. "It really gives you a new insight into a mechanism and really lays out a road map for developing new therapeutics."

"Ultimately, we are seeing an underlying deficiency in copper, but at a sub-cellular level,” added Stys. "Unfortunately, because of the way that the body regulates copper, we can't simply eat more of a certain kind of food or take a copper supplement to compensate.

"What we are looking at now is the development of a drug that acts on the NMDA receptor to mimic the effect of copper in the brain."

Bill Gaudette, CEO of the Alzheimer Society of Alberta and the Northwest Territories, said the results of the study are very promising.

"Finding a cure for Alzheimer's disease and dementia is really like a puzzle and this is one of the pieces in that jigsaw puzzle," he said.

There are over 5.4 million Americans with Alzheimer’s disease or related dementia, according to the Alzheimer's Association.

jenna.mcmurray@sunmedia.ca

Friday, January 27, 2012

More promising news on the Alzheimer's research front

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitterVancover Sun

BY EVA FERGUSON, POSTMEDIA NEWS

CALGARY — A new study by researchers at the University of Calgary's Hotchkiss Brain Institute is challenging the conventional thinking about how brain cells die in Alzheimer's disease, and may one day lead to effective treatment for the memory-ravaging condition.

Researchers Peter Stys and Gerald Zamponi have shown that brain cells of Alzheimer's patients are dying because of malfunctions in key receptors known as NMDA receptors, which are critical for memory and learning.

"We've shown that the NMDA receptor functions improperly when there is too much alpha beta (a protein) around the ,NMDA receptor" says Zamponi, head of the university's department of physiology and pharmacology.

"So the key now is to find out how to reverse this, and find the right drug that regulates the NMDA receptor."

And by reversing that malfunction, scientists may one day be able to reverse the effects of Alzheimer's.

Zamponi says the University of Calgary is now working with the Centre for Drug Discovery Research and Development in Vancouver, screening hundreds of thousands of drugs to find one that is safe and successfully regulates NMDA.

It may take about two to three years to get to clinical trials, then another four to five years to complete them.

Gaudette says in all his years of working with Alzheimer's patients and their families, this is the most exciting discovery yet, calling it a potential "game changer" for everyone involved in dementia research and care.

"This offers hope. It's a ray of light for people who suffer from this terrible disease."

Alzheimer's disease destroys brain cells and results in memory loss, changes in mood and behaviour, and difficulty with day-to-day tasks.

While it is most commonly diagnosed in adults over the age of 65, more and more cases are being diagnosed in people in their 50s and sometimes even in their 40s.

"Ten years ago, that was unheard of. But we have better diagnoses, better awareness, and people feel more comfortable now getting a diagnosis."

Gaudette encourages anyone who may suspect they are showing symptoms of early onset to go to see their doctor because early diagnoses can lead to early intervention and drug therapy which can significantly slow down progression on the disease.

Zamponi and Stys' research was funded by Alberta Innovates-Health Solutions.

Tuesday, October 13, 2009

New Findings About Brain Proteins Suggest Possible Way To Fight Alzheimer's (part 2)

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting activities



ScienceDaily

Dr. Herz said the study is especially important because this mechanism involves another protein involved in Alzheimer's called ApoE4, which is the primary risk factor for the most frequent late-onset form of the disease. The receptor that binds to ApeE molecules also binds to Reelin, and is part of the red-light/green-light complex that controls the sensitivity of the NMDA receptors.

"These results imply that Reelin, ApoE and beta-amyloid converge on the same molecular mechanism, which is critical in the Alzheimer's disease process, and Reelin may be a common factor to fight both beta-amyloid and mutated ApoE," Dr. Herz said. "This study establishes a rationale that ApoE receptors have an action that can keep the Alzheimer's disease process at bay by preventing damage in the first place."

The researchers are currently studying the role of ApoE4 in this mechanism. Mimicking or preserving normal Reelin function to stimulate the ApoE receptors might provide a path to stave off the disease, Dr. Herz said.

Other UT Southwestern authors included lead author Dr. Murat Durakoglugil, assistant instructor of molecular genetics; graduate student Ying Chen; Dr. Charles White, professor of pathology; and Dr. Ege Kavalali, associate professor of neuroscience.

The study was funded by the National Institutes of Health, the American Health Assistance Foundation, the Perot Family Foundation and the Humboldt Foundation.

Monday, October 12, 2009

New Findings About Brain Proteins Suggest Possible Way To Fight Alzheimer's (part 1)

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting activities



ScienceDaily — The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.

The findings, available online in the journal Proceedings of the National Academy of Sciences, suggest a promising new tactic against the devastating illness, the researchers said.

The harmful protein, called beta-amyloid, is found in the brain and, when functioning properly, suppresses nerve activity involved with memory and learning. Its normal function can be likened to a red traffic light, restraining nerve cells from getting overexcited when they receive stimulating signals from neighboring cells. People with Alzheimer's disease, however, accumulate too much beta-amyloid – the traffic light gets stuck on "red" and nerve cells become less responsive.

Another brain protein, called Reelin, acts as a "green light," stimulating nerve cells to respond more strongly to their neighbors' signals.

The new study shows that applying Reelin directly to brain slices from mice prevents excess beta-amyloid from completely silencing nerves.

"If we can identify a mechanism to keep the nerve cells functioning strongly, that might provide a way to fight Alzheimer's disease," said Dr. Joachim Herz, professor of molecular genetics and neuroscience at UT Southwestern and the study's senior author.

In the study, the researchers recorded electrical currents in the mouse hippocampus, an area of the brain associated with learning and memory. From their experiments they determined that Reelin and beta-amyloid interact with the same protein complex, called an NMDA receptor, which plays an important role in coordinating chemical signals between adjacent nerve cells.

They found that Reelin activates and strengthens the response of the NMDA receptor. In the presence of too much beta-amyloid, the receptor migrates into the cell, reducing the cell's sensitivity to incoming signals. By contrast, in strong concentrations of Reelin, the receptor remains active and the cell has the green light to continue receiving normally.

Dr. Herz said the study is..........comeback tomorrow to read part 2 of.... New Findings About Brain Proteins Suggest Possible Way To Fight Alzheimer's
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info